Herpes simplex viruses 1 and 2. (Q34743418)

4 August 2017

1 reference

title

Herpes simplex viruses 1 and 2. (English)

1 reference

4 August 2017

Kimberly A Yeung-Yue

1

1 reference

4 August 2017

Mathijs H Brentjens

series ordinal

2

1 reference

4 August 2017

Patricia C Lee

series ordinal

3

1 reference

4 August 2017

Stephen K Tyring

series ordinal

4

1 reference

4 August 2017

1 April 2002

1 reference

4 August 2017

1 reference

4 August 2017

20

1 reference

4 August 2017

249-266

1 reference

4 August 2017

2

1 reference

4 August 2017

Herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus type 2 in the United States, 1976 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Risk Factors for the Sexual Transmission of Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Effect of Condoms on Reducing the Transmission of Herpes Simplex Virus Type 2 From Men to Women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recurrence rates in genital herpes after symptomatic first-episode infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Virologic characteristics of subclinical and symptomatic genital herpes infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

The Association Between Genital Ulcer Disease and Acquisition of HIV Infection in Homosexual Men

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

High cumulative incidence of genital herpes amongst HIV-1 seropositive heterosexuals in south London

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Prior herpes simplex virus type 2 infection as a risk factor for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Epidemiological Synergy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

The impact of active herpes simplex virus infection on human immunodeficiency virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfected women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Infections with herpes simplex viruses (1).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Management of neonatal herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Persistent stress as a predictor of genital herpes recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Demonstration of Exogenous Genital Reinfection with Herpes Simplex Virus Type 2 by Restriction Endonuclease Fingerprinting of Viral DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Reinfection is an Uncommon Occurrence in Patients with Symptomatic Recurrent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Experimental human reinfection with herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Reactions of autoinoculation for recurrent herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

The heterogeneous clinical spectrum of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex: evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Genital herpes simplex virus infections: clinical manifestations, course, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Genital Herpetic Infection in Men and Women: Clinical Course and Effect of Topical Application of Adenine Arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes. Atypical clinical manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Urinary Retention Probably Secondary to Herpes Genitalis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recurrent Conjugal Neuralgia Caused by Herpesvirus Hominis Type 2

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Aseptic meningitis in association with herpes progenitalis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Genital herpes complicating pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Intrauterine herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpetic whitlow. Epidemiology, clinical characteristics, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Viral folliculitis. Atypical presentations of herpes simplex, herpes zoster, and molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Common ocular infections. A prescriber's guide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Virus infections of the eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir for recurrent erythema multiforme caused by herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Relation between herpes simplex viruses and human immunodeficiency virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir Prevents Reactivation of Herpes Simplex Labialis in Skiers

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Tests for detecting herpes simplex virus and varicella-zoster virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Sorting out the new HSV type specific antibody tests

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2 [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

An evaluation of near patient tests for detecting herpes simplex virus type-2 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Drugs five years later: acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir: Mechanism of Action, Pharmacokinetics, Safety and Clinical Applications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Renal function after acyclovir intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir-induced renal failure: course and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acute renal failure and coma secondary to acyclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Severe but reversible neurotoxicity from acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Neurologic Symptoms Associated with Parenteral Acyclovir Treatment After Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Treatment of recurrent herpes simplex labialis with oral acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Double-blind Placebo-Controlled Trial of Oral Acyclovir in First-Episode Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Intravenous Acyclovir for the Treatment of Primary Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus resistant to acyclovir. A study in a tertiary care center

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Mechanism of action of foscarnet against viral polymerases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Foscarnet-resistant herpes simplex virus infection in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Antiviral therapy of herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Herpesvirus vaccines. Development, controversies, and applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Prospects for control of herpes simplex virus disease through immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2801%2900003-1

7 January 2021

10.1016/S0733-8635(01)00003-1

Identifiers

DOI

1 reference

4 August 2017

1 reference